Ohio Department of Medicaid (ODM) Drug Utilization Review (DUR) Board Quarterly Meeting
February 9, 2021

The ODM DUR Board meeting was called to order at 12:04 PM EST via GoToMeeting
https://attendee.gotowebinar.com/register/4124977711676393740
Stacey Rexrode-Brewer, Pharm.D. presided

The following Board members were present:
Scott Baran, R.Ph.
David Brookover, R.Ph.
Michael Dietz, D.O. Michael
Farrell, M.D., Co-Chair A.
Mehran Mostafavifar, M.D.
Lenard G. Presutti, D.O.
Stacey Rexrode-Brewer Pharm.D., Chair
Donald Sullivan Ph.D., R.Ph.

Also present from ODM were Michelle Barger, Pharm.D. and Sean Eckard, B.S. Pharm.D. Change
Healthcare attendees included Jill R.K. Griffith B.S. Pharm.D., Gail Master, R.Ph., and Philip Verret,
Pharm. D. Approximately 30 observers were present.

The Conflict of Interest Statement

Signed 2021 Conflict of Interest Statements were received from each DUR Board member in advance of the
meeting. The Conflict of Interest Statement was reviewed with the Board.

Roll Call and Review of Previous Minutes

The November 10, 2020 DUR Board Meeting Minutes were approved.

DUR Committee Report

G. Master presented the re-review results from the intervention directed at prescribers whose patients were
less than 70% adherent to their antiepileptic medication. She then presented the intervention directed at
prescribers whose patients were not filling their HIV medication at a rate to ensure 95% or greater
compliance.

Next, G. Master presented the intervention directed at prescribers whose patients were identified as taking
a proton pump inhibitor (PPI) for longer than 6 months.

Lastly, G. Master provided an update to the Board on Coordinated Services Program (CSP) membership. There
are currently 190 Fee-for-Service members enrolled in the program. She also announced an update on the
new rule that began on January 1, 2021.
Health Plan Policy Update

S. Baran presented the Ohio Medicaid Health Plan Policy update. ODM has implemented the Pharmacists as Providers initiative which reimburses pharmacists for clinical services provided to members. Through this program, pharmacists may receive payment for three clinical services: managing drug therapy under a consult agreement, administering immunizations, and administering certain other injectable medications. ODM anticipates this program will yield significant clinical benefits, including improved therapeutic outcomes for high-risk medical conditions, fewer medication-related adverse reactions and errors, and enhanced collaboration among medical disciplines.

Also, enrolled pharmacies can now begin submitting claims for COVID-19 point-of-care testing to ODM. This initiative is an important addition to Ohio’s testing infrastructure because it provides a mechanism to increase the availability of rapid testing in the community. With the completion of this project, pharmacies are now able to perform COVID-19 testing via two mechanisms: a swab and send model in partnership with a clinical laboratory, or via rapid testing at the pharmacy. In addition to testing, ODM is now accepting COVID-19 vaccine claims.

Next, the Centers for Medicare and Medicaid Services (CMS) Federal Fiscal Year (FFY) 2019 Annual DUR Report has been posted to the Medicaid.gov website. This was the second year that Managed Care Plans submitted reports in addition to Fee-For-Service reports.

Also, every two years ODM conducts a Cost of Dispensing Survey. The survey was administered to ODM enrolled pharmacies and the final 2020 report has been posted on the Ohio Medicaid Pharmacy website.

Next, ODM announced Gainwell Technologies as the vendor for the agency’s Single Pharmacy Benefits Manager (SPBM). This news is the culmination of a 2019 Ohio Legislature directive for ODM to select and contract with a single PBM to improve management and administration of pharmacy benefits for managed care members. Through the SPBM, ODM will gain increased financial accountability and ensure alignment with clinical and policy goals, while also improving transparency.

Lastly, ODM has updated the format of the Unified Preferred Drug List (UPDL). The new design is intended to be a cleaner layout and more user friendly for providers. This new format is now viewable on the pharmacy website.

Unfinished Business

There was no unfinished business.

New Business

G. Master presented an overview of a RetroDUR intervention directed at prescribers whose patients are receiving opioid medications exceeding eighty Morphine Equivalent Doses (MED) per day. The Board reviewed the letter and made recommendations.

Next, S. Baran presented the new UPDL format.

Dr. Eckard then provided an overview of how pharmacies are able to submit claims for administering the COVID-19 Vaccine.
Next, G. Master explained the Additional Therapeutic Classes with Clinical Criteria document and announced that the DUR Committee has been reviewing this document and making recommendations. In addition, Change Healthcare’s Medical Directors review the recommendations.

**Announcements**

The 2021 calendar was reviewed. The RetroDUR intervention for March will focus on members who are taking triple antithrombotic therapy. A discussion ensued to identify proper messaging to prescribers.

The dates for the 2021 DUR Board meetings were reviewed:
- May 11, 2021
- September 21, 2021
- November 9, 2021

**Adjournment**

The meeting was adjourned at 1:11 PM.